Sun Pharmaceutical zooms on inking pact to acquire all outstanding shares of Organon

Sun Pharmaceutical Industries is currently trading at Rs. 1751.00, up by 131.05 points or 8.09% from its previous closing of Rs. 1619.95 on the BSE. The scrip opened at Rs. 1632.50 and has traded between Rs. 1,766.65 and Rs. 1621.00. The BSE group 'A' stock of face value Rs. 1 has reached a 52-week high of Rs. 1850.95 on 02-May-2025 and a 52-week low of Rs. 1547.25 on 26-Sep-2025. Last week’s high and low were Rs. 1,819.15 and Rs. 1614.20, respectively. The current market cap of Sun Pharmaceutical Industries is Rs. 414689.06 crore. Promoters hold 54.48% of the shares, while institutions and non-institutions hold 37.03% and 8.48%, respectively. Sun Pharmaceutical Industries (Sun Pharma) has entered into a definitive agreement to acquire all outstanding shares of Organon & Co. for $14.00 per share in an all-cash transaction, valued at $11.75 billion. Organon, a global healthcare company formed through a spinoff from Merck (MSD outside the U.S. and Canada) in 2021, will be fully acquired by Sun Pharma. This deal aligns with Sun Pharma’s strategy of expanding its Innovative Medicines business and strengthening its position in Established Brands/Branded Generics. The acquisition also enables Sun Pharma to enter the biosimilars market as a top-10 global player. Organon’s portfolio, global footprint, and stakeholder relationships will complement Sun Pharma’s existing strengths, enhancing long-term value creation. The transaction has been approved by the boards of both companies and is subject to regulatory approvals and shareholder consent. Upon completion, Sun Pharma will be among the top 25 global pharmaceutical companies, with a combined revenue of $12.4 billion. The deal positions Sun Pharma as a leading player in Established Brands/Branded Generics, a more focused Innovative Medicines company with 27% revenue share, and a top 3 company in global Women’s Health. It will also make Sun Pharma the 7th largest global biosimilar player, with a presence in 150 countries, including 18 major markets generating over $100 million in revenue each.